Growth Metrics

Pfizer (PFE) Long-Term Deferred Tax (2016 - 2026)

Pfizer has reported Long-Term Deferred Tax over the past 18 years, most recently at $10.0 billion for Q1 2026.

  • Quarterly Long-Term Deferred Tax rose 4.43% to $10.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.0 billion through Mar 2026, up 4.43% year-over-year, with the annual reading at $9.7 billion for FY2025, 11.97% up from the prior year.
  • Long-Term Deferred Tax was $10.0 billion for Q1 2026 at Pfizer, up from $9.7 billion in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $11.0 billion in Q3 2025 and troughed at $3.7 billion in Q4 2023.
  • The 5-year median for Long-Term Deferred Tax is $7.9 billion (2024), against an average of $7.9 billion.
  • Year-over-year, Long-Term Deferred Tax skyrocketed 159.91% in 2022 and then tumbled 44.63% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $6.7 billion in 2022, then tumbled by 44.63% to $3.7 billion in 2023, then surged by 133.73% to $8.7 billion in 2024, then rose by 11.97% to $9.7 billion in 2025, then rose by 2.74% to $10.0 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Long-Term Deferred Tax are $10.0 billion (Q1 2026), $9.7 billion (Q4 2025), and $11.0 billion (Q3 2025).